The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials - PubMed (original) (raw)
Meta-Analysis
. 2012 May;69(5):1213-20.
doi: 10.1007/s00280-012-1828-8. Epub 2012 Jan 24.
Affiliations
- PMID: 22271210
- DOI: 10.1007/s00280-012-1828-8
Meta-Analysis
The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials
Ye-min Wang et al. Cancer Chemother Pharmacol. 2012 May.
Abstract
Background: Recently, melatonin has been associated with cancer both in vitro and in vivo. However, the value of melatonin in the treatment of cancer remains disputable. Hence, we performed a systematic review of randomized controlled trials (RCTs) of melatonin in solid tumor cancer patients and observed its effect on tumor remission, 1-year survival, and side effects due to radiochemotherapy.
Methods: An electronic search was conducted using the databases Pubmed, Medline, EMBASE, Cochrane library, and CNKI, from inception to November 2011. Trials using melatonin as adjunct treatment concurrent with chemotherapy or radiotherapy for cancer were included. Pooled relative risk (RR) for the tumor remission, 1-year survival, and radiochemotherapy-related side effects were calculated using the software Revman 5.0.
Results: The search strategy identified 8 eligible RCTs (n = 761), all of which studied solid tumor cancers. The dosage of melatonin used in the 8 included RCTs was 20 mg orally, once a day. Melatonin significantly improved the complete and partial remission (16.5 vs. 32.6%; RR = 1.95, 95% CI, 1.49-2.54; P < 0.00001) as well as 1-year survival rate (28.4 vs. 52.2%; RR = 1.90; 95% CI, 1.28-2.83; P = 0.001), and dramatically decreased radiochemotherapy-related side effects including thrombocytopenia (19.7 vs. 2.2%; RR = 0.13; 95% CI, 0.06-0.28; P < 0.00001), neurotoxicity (15.2 vs. 2.5%; RR = 0.19; 95% CI, 0.09-0.40; P < 0.0001), and fatigue (49.1 vs. 17.2%; RR = 0.37; 95% CI, 0.28-0.48; P < 0.00001). Effects were consistent across different types of cancer. No severe adverse events were reported.
Conclusions: Melatonin as an adjuvant therapy for cancer led to substantial improvements in tumor remission, 1-year survival, and alleviation of radiochemotherapy-related side effects.
Similar articles
- Systemic treatments for metastatic cutaneous melanoma.
Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Pasquali S, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. PMID: 33871055 Free PMC article. Updated. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. PMID: 29271481 Free PMC article. Updated. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, Mazaud C, Phan C, Hughes C, Riddle D, Naldi L, Garcia-Doval I, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3. Cochrane Database Syst Rev. 2020. PMID: 31917873 Free PMC article. Updated. - Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG. McDonald JW, et al. Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi: 10.1002/14651858.CD003459.pub3. Cochrane Database Syst Rev. 2012. PMID: 23235598 Updated.
Cited by
- Neurodevelopmental Consequences of Pediatric Cancer and Its Treatment: The Role of Sleep.
Mogavero MP, Bruni O, DelRosso LM, Ferri R. Mogavero MP, et al. Brain Sci. 2020 Jul 1;10(7):411. doi: 10.3390/brainsci10070411. Brain Sci. 2020. PMID: 32630162 Free PMC article. Review. - Melatonin and neuroblastoma: a novel therapeutic approach.
Pourhanifeh MH, Kamali M, Mehrzadi S, Hosseinzadeh A. Pourhanifeh MH, et al. Mol Biol Rep. 2021 May;48(5):4659-4665. doi: 10.1007/s11033-021-06439-1. Epub 2021 Jun 1. Mol Biol Rep. 2021. PMID: 34061325 Review. - Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis.
Wang Y, Wang P, Zheng X, Du X. Wang Y, et al. Onco Targets Ther. 2018 Nov 8;11:7895-7908. doi: 10.2147/OTT.S174100. eCollection 2018. Onco Targets Ther. 2018. PMID: 30510430 Free PMC article. - Melatonin limits paclitaxel-induced mitochondrial dysfunction in vitro and protects against paclitaxel-induced neuropathic pain in the rat.
Galley HF, McCormick B, Wilson KL, Lowes DA, Colvin L, Torsney C. Galley HF, et al. J Pineal Res. 2017 Nov;63(4):e12444. doi: 10.1111/jpi.12444. Epub 2017 Sep 22. J Pineal Res. 2017. PMID: 28833461 Free PMC article. - [Melatonin inhibits growth and metastasis of MDA-MB-231 breast cancer cells by activating autophagy].
Wu D, Zhang Y, Tang H, Yang J, Li M, Liu H, Li Q. Wu D, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2022 Feb 20;42(2):278-285. doi: 10.12122/j.issn.1673-4254.2022.02.16. Nan Fang Yi Ke Da Xue Xue Bao. 2022. PMID: 35365454 Free PMC article. Chinese.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources